As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A carries a market capitalization of 9.08B, placing it among publicly traded companies globally. Its enterprise value stands at 7.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.08B |
| Enterprise Value | 7.36B |
Vcanbio Cell & Gene Engineering Corp., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.
| Earnings Date | 4/23/2027 |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A has 467.95M shares outstanding.
| Shares Outstanding | 467.95M |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A trades at a trailing price-to-earnings ratio of 79.88. The price-to-sales ratio is 6.54, and the price-to-book ratio stands at 2.38.
| PE Ratio | 79.88 |
| PS Ratio | 6.54 |
| PB Ratio | 2.38 |
| P/TBV Ratio | 3.06 |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A trades at an EV/EBITDA multiple of 38.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 38.94 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.36B versus a market cap of 9.08B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 5.35 |
| EV / EBITDA | 38.94 |
| EV / EBIT | 38.94 |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.93 |
| Quick Ratio | 1.29 |
| Debt / Equity | 1.68 |
| Debt / EBITDA | 0.34 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 710,828.59 in revenue per employee across its workforce of 1,935.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 710,828.59 |
| Employee Count | 1,935.00 |
Over the twelve months ended September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A recorded 80.09M in income tax expense. That works out to an effective tax rate of 42.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 186.78M, leaving 112.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 80.09M |
| Effective Tax Rate | 42.88 |
As of the close on November 17, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A's stock has declined approximately 41.26% over the past 52 weeks. The 50-day moving average sits at 18.00, while the 200-day moving average is 22.13.
| 52-Week Price Change | -41.26% |
| 50-Day Moving Average | 18.00 |
| 200-Day Moving Average | 22.13 |
Over the twelve months ended September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A generated 1.38B in revenue and converted that into 112.54M in net income, yielding earnings per share of 0.23. EBITDA reached 188.90M, while operating income came in at 192.91M.
| Revenue | 1.38B |
| Gross Profit | 986.02M |
| Operating Income | 192.91M |
| Pretax Income | 186.78M |
| Net Income | 112.54M |
| EBITDA | 188.90M |
| EBIT | 188.90M |
| Earnings Per Share (EPS) | 0.23 |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A holds 1.83B in cash and equivalents against 64.67M in total debt, resulting in a net debt position of -1.23B. Total book value stands at 3.82B, with working capital of 1.32B providing operational flexibility.
| Cash & Cash Equivalents | 1.83B |
| Total Debt | 64.67M |
| Net Debt | -1.23B |
| Equity (Book Value) | 3.82B |
| Book Value Per Share | 8.16 |
| Working Capital | 1.32B |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -41.44M |
Over the twelve months ended September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A posted a gross margin of 71.69, reflecting its pricing power and cost economics. The operating margin of 14.03 and net profit margin of 8.18 provide insight into operational efficiency.
| Gross Margin | 71.69 |
| Operating Margin | 14.03 |
| Pretax Margin | 13.58 |
| Profit Margin | 8.18 |
| EBITDA Margin | 13.73 |
These figures cover the twelve months ended September 30, 2026. Total shareholder yield reaches 0.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vcanbio Cell & Gene Engineering Corp., Ltd. Class A shareholders.
| Shareholder Yield | 0.50 |
Vcanbio Cell & Gene Engineering Corp., Ltd. Class A's most recent stock split took place on August 10, 2001 with a 5:8 split ratio.
| Last Split Date | 8/10/2001 |
| Split Ratio | 5:8 |
As of September 30, 2026, Vcanbio Cell & Gene Engineering Corp., Ltd. Class A has an Altman Z-Score of 4.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.45 |
Already premium?